OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	348
Prioritising health equity alongside donation safety – Authors' reply	278
Zanubrutinib-associated ecchymotic lesions	200
In the trenches	174
Correction to Lancet Haematol 2024; 11: e114–26	172
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	149
Correction to Lancet Haematol 2023; 10: e333–45	140
MRD-guided treatment cessation in multiple myeloma	129
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	122
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	118
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	115
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	112
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	108
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	94
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	92
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	90
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	90
Bedside art is good medicine	89
Artwork from trauma: the social life of medical data	87
CAR T cells in CNS-relapsed leukaemia: one step forward	80
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	75
International Society on Thrombosis and Haemostasis Congress 2023	72
Be compliant or compromise?	72
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	70
Correction to Lancet Haematol 2025; 12: e294–303	70

Blood cell defence against pathogens	69
Rituximab versus active surveillance in patients with follicular lymphoma	68
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	68
Correction to Lancet Haematol 2023; 10: e433–44	68
Blood deserts: a vision to tackle blood inaccessibility	68
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	65
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	65
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	62
Production and supply of blood products in Brazil	62
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	61
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	61
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	61
Anaemia in a time of climate crisis	59
Extensively distributed erythema nodosum in VEXAS syndrome	59
USAID's enduring impact on anaemia management must be preserved	58
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	57
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	56
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	56
Sickle cell disease in India: current status and progress	55
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	54
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	53
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	53
Living with sickle cell disease: voices from sub-Saharan Africa	53
Universal health coverage for children with cancer	51
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	51
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	51